Location History:
- Gotenba, JP (2008 - 2013)
- Kanagawa, JP (2011 - 2018)
Company Filing History:
8 out of 949 
2 out of 216 
1 out of 35 Years Active: 2008-2018
Title: Masamichi Sugimoto: Innovator in Antibody Development
Introduction
Masamichi Sugimoto is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer treatment. With a total of 8 patents to his name, Sugimoto's work has the potential to impact cancer therapies significantly.
Latest Patents
One of Sugimoto's latest patents involves an anti-glypican-3 antibody. This antibody comprises one or more amino acid substitutions introduced in the Fc region. Specifically, the invention highlights that one or more of the amino acid residues at positions 239, 298, 326, 330, and 332 in the Fc region can be substituted with other amino acid residues. The Fc-modified anti-glypican-3 antibody exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC) activity, making it useful in treating various cancers, including hepatic cancer. Additionally, the patent discloses an anticancer agent that includes the anti-glypican-3 antibody and a pharmaceutically acceptable carrier. It also outlines a method for treating cancer patients by administering this anticancer agent.
Career Highlights
Throughout his career, Masamichi Sugimoto has worked with notable companies in the biotechnology sector. He has been associated with Chugai Seiyaku Kabushiki Kaisha and Xencor, Inc., where he has contributed to various innovative projects. His expertise in antibody development has positioned him as a key figure in the industry.
Collaborations
Sugimoto has collaborated with several professionals in his field, including Hiroaki Ito and Kazuyuki Yoshizaki. These collaborations have further enhanced his research and development efforts in biotechnology.
Conclusion
Masamichi Sugimoto's innovative work in the development of antibodies, particularly for cancer treatment, showcases his significant contributions to biotechnology. His patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.